Symbols / NMRA
NMRA Chart
About
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 547.20M |
| Enterprise Value | 386.59M | Income | -236.30M | Sales | — |
| Book/sh | 0.82 | Cash/sh | 1.03 | Dividend Yield | — |
| Payout | 0.00% | Employees | 95 | IPO | — |
| P/E | — | Forward P/E | -3.24 | PEG | — |
| P/S | — | P/B | 3.95 | P/C | — |
| EV/EBITDA | -1.61 | EV/Sales | — | Quick Ratio | 6.64 |
| Current Ratio | 6.85 | Debt/Eq | 15.20 | LT Debt/Eq | — |
| EPS (ttm) | -1.47 | EPS next Y | -1.00 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-13 | ROA | -56.71% |
| ROE | -104.35% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 169.94M |
| Shs Float | 82.06M | Short Float | 9.06% | Short Ratio | 3.44 |
| Short Interest | — | 52W High | 3.65 | 52W Low | 0.61 |
| Beta | 2.53 | Avg Volume | 1.66M | Volume | 1.08M |
| Target Price | $8.91 | Recom | None | Prev Close | $3.02 |
| Price | $3.22 | Change | 6.62% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.91
Mean price target
2. Current target
$3.22
Latest analyst target
3. DCF / Fair value
$-12.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.22
Low
$3.00
High
$18.00
Mean
$8.91
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | up | William Blair | Market Perform → Outperform | — |
| 2026-01-12 | init | Leerink Partners | — → Outperform | $8 |
| 2025-12-01 | up | RBC Capital | Sector Perform → Outperform | $7 |
| 2025-11-17 | main | Stifel | Hold → Hold | $3 |
| 2025-10-28 | main | Needham | Buy → Buy | $8 |
| 2025-10-27 | up | Guggenheim | Neutral → Buy | $14 |
| 2025-09-16 | down | JP Morgan | Neutral → Underweight | — |
| 2025-07-16 | main | Mizuho | Outperform → Outperform | $5 |
| 2025-05-13 | reit | Needham | Buy → Buy | $5 |
| 2025-04-10 | reit | Needham | Buy → Buy | $5 |
| 2025-04-02 | down | B of A Securities | Buy → Underperform | $1 |
| 2025-03-10 | down | Guggenheim | Buy → Neutral | — |
| 2025-03-07 | down | Stifel | Buy → Hold | $2 |
| 2025-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-03-04 | reit | RBC Capital | Sector Perform → Sector Perform | $4 |
| 2025-03-04 | reit | Needham | Buy → Buy | $5 |
| 2025-03-04 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-02-14 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-01-06 | main | B of A Securities | Buy → Buy | $7 |
| 2025-01-03 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
- Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity - Yahoo! Finance Canada ue, 10 Mar 2026 00
- $NMRA stock is down 11% today. Here's what we see in our data. - Quiver Quantitative Mon, 02 Mar 2026 15
- William Blair Upgrades Neumora Therapeutics (NMRA) - Nasdaq ue, 17 Feb 2026 08
- Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 - Finviz Wed, 04 Mar 2026 16
- Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down - Time to Sell? - MarketBeat Mon, 02 Mar 2026 18
- Joshua Pinto Sells 5,967 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock - MarketBeat hu, 19 Feb 2026 08
- $NMRA stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 09 Feb 2026 08
- 11 Most Popular AI Penny Stocks to Buy Now - Insider Monkey Mon, 09 Mar 2026 14
- RBC Sees Upside Potential in Neumora Therapeutics (NMRA) - Yahoo Finance Sat, 03 Jan 2026 08
- Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up After Analyst Upgrade - MarketBeat ue, 17 Feb 2026 08
- Neumora Therapeutics Stock (NMRA) Opinions on Obesity Drug Data Release - Quiver Quantitative hu, 30 Oct 2025 07
- Neumora Therapeutics (NASDAQ:NMRA) Insider Paul Berns Sells 9,819 Shares - MarketBeat hu, 19 Feb 2026 08
- Insider Purchase: Director at $NMRA Buys 1,915,700 Shares - Quiver Quantitative Wed, 29 Oct 2025 07
- Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 6,165 Shares of Stock - MarketBeat hu, 19 Feb 2026 08
- Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating - Yahoo Finance hu, 30 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 9819 | 34459 | — | Sale at price 3.51 per share. | BERNS PAUL L | Chief Executive Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 6165 | 21917 | — | Sale at price 3.56 per share. | AURORA DALJIT SINGH | Chief Operating Officer | — | 2026-02-17 00:00:00 | D |
| 2 | 5967 | 21093 | — | Sale at price 3.54 per share. | PINTO JOSHUA PH.D. | President | — | 2026-02-17 00:00:00 | D |
| 3 | 1436 | 5119 | — | Sale at price 3.56 per share. | MILLIGAN MICHAEL LEE | Chief Financial Officer | — | 2026-02-17 00:00:00 | D |
| 4 | 114703 | 307026 | — | Sale at price 2.68 per share. | AURORA DALJIT SINGH | Chief Operating Officer | — | 2025-11-11 00:00:00 | I |
| 5 | 1915700 | 4999977 | — | Purchase at price 2.61 per share. | BUROW KRISTINA M | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-27 00:00:00 | I |
| 6 | 1915700 | 4999977 | — | Purchase at price 2.61 per share. | ARCH VENTURE PARTNERS XII, LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-27 00:00:00 | I |
| 7 | 13202 | — | — | Stock Gift at price 0.00 per share. | PINTO JOSHUA PH.D. | President | — | 2025-05-21 00:00:00 | D |
| 8 | 13871 | 23468 | — | Sale at price 1.69 per share. | BERNS PAUL L | Chief Executive Officer | — | 2025-02-18 00:00:00 | D |
| 9 | 8565 | 14347 | — | Sale at price 1.68 per share. | AURORA DALJIT SINGH | Officer | — | 2025-02-18 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -262.83M | -251.43M | -135.28M | -236.78M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -243.79M | -235.93M | -130.90M | -237.31M |
| ReconciledDepreciation | 631.00K | 668.00K | 594.00K | 538.00K |
| EBITDA | -262.83M | -251.43M | -135.28M | -236.78M |
| EBIT | -263.46M | -252.10M | -135.87M | -237.32M |
| NetInterestIncome | 19.93M | 16.61M | 4.56M | 0.00 |
| InterestIncome | 19.93M | 16.61M | 4.56M | 0.00 |
| NormalizedIncome | -243.79M | -235.93M | -130.90M | -237.31M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -243.79M | -235.93M | -130.90M | -237.31M |
| TotalExpenses | 263.46M | 252.10M | 135.87M | 237.32M |
| TotalOperatingIncomeAsReported | -263.46M | -252.10M | -135.87M | -237.32M |
| DilutedAverageShares | 159.38M | 65.02M | 151.95M | 151.95M |
| BasicAverageShares | 159.38M | 65.02M | 151.95M | 151.95M |
| DilutedEPS | -1.53 | -3.63 | -0.86 | -1.56 |
| BasicEPS | -1.53 | -3.63 | -0.86 | -1.56 |
| DilutedNIAvailtoComStockholders | -243.79M | -235.93M | -130.90M | -237.31M |
| NetIncomeCommonStockholders | -243.79M | -235.93M | -130.90M | -237.31M |
| NetIncome | -243.79M | -235.93M | -130.90M | -237.31M |
| NetIncomeIncludingNoncontrollingInterests | -243.79M | -235.93M | -130.90M | -237.31M |
| NetIncomeContinuousOperations | -243.79M | -235.93M | -130.90M | -237.31M |
| TaxProvision | 178.00K | 268.00K | 0.00 | |
| PretaxIncome | -243.61M | -235.66M | -130.90M | -237.31M |
| OtherIncomeExpense | -78.00K | -170.00K | 405.00K | 11.00K |
| OtherNonOperatingIncomeExpenses | -78.00K | -170.00K | 405.00K | 11.00K |
| NetNonOperatingInterestIncomeExpense | 19.93M | 16.61M | 4.56M | 0.00 |
| InterestIncomeNonOperating | 19.93M | 16.61M | 4.56M | 0.00 |
| OperatingIncome | -263.46M | -252.10M | -135.87M | -237.32M |
| OperatingExpense | 263.46M | 252.10M | 135.87M | 237.32M |
| ResearchAndDevelopment | 200.93M | 206.62M | 104.75M | 212.78M |
| SellingGeneralAndAdministration | 62.54M | 45.48M | 31.12M | 24.55M |
| GeneralAndAdministrativeExpense | 62.54M | 45.48M | 31.12M | 24.55M |
| OtherGandA | 62.54M | 45.48M | 31.12M | 24.55M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 161.71M | 158.83M | 151.95M | 151.95M |
| ShareIssued | 161.71M | 158.83M | 151.95M | 151.95M |
| TotalDebt | 1.85M | 5.23M | 8.44M | 2.05M |
| TangibleBookValue | 287.06M | 469.08M | -446.85M | -325.22M |
| InvestedCapital | 287.06M | 469.08M | -446.85M | -325.22M |
| WorkingCapital | 284.17M | 453.17M | 364.26M | 392.32M |
| NetTangibleAssets | 287.06M | 469.08M | -446.85M | -325.22M |
| CapitalLeaseObligations | 1.85M | 5.23M | 8.44M | 2.05M |
| CommonStockEquity | 287.06M | 469.08M | -446.85M | -325.22M |
| TotalCapitalization | 287.06M | 469.08M | -446.85M | -325.22M |
| TotalEquityGrossMinorityInterest | 287.06M | 469.08M | -446.85M | -325.22M |
| StockholdersEquity | 287.06M | 469.08M | -446.85M | -325.22M |
| GainsLossesNotAffectingRetainedEarnings | 62.00K | -76.00K | -774.00K | 0.00 |
| OtherEquityAdjustments | 62.00K | -76.00K | -774.00K | |
| RetainedEarnings | -947.22M | -703.43M | -467.51M | -336.61M |
| AdditionalPaidInCapital | 1.23B | 1.17B | 21.43M | 11.38M |
| CapitalStock | 16.00K | 16.00K | 3.00K | 3.00K |
| CommonStock | 16.00K | 16.00K | 3.00K | 3.00K |
| TotalLiabilitiesNetMinorityInterest | 29.91M | 27.12M | 873.08M | 754.52M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 22.00K | 2.01M | 849.39M | 731.24M |
| OtherNonCurrentLiabilities | 22.00K | 155.00K | 628.00K | 386.00K |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 843.69M | 729.86M |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 1.85M | 5.07M | 996.00K |
| LongTermCapitalLeaseObligation | 0.00 | 1.85M | 5.07M | 996.00K |
| CurrentLiabilities | 29.89M | 25.11M | 23.70M | 23.28M |
| OtherCurrentLiabilities | 133.00K | 139.00K | 1.64M | 1.49M |
| CurrentDebtAndCapitalLeaseObligation | 1.85M | 3.38M | 3.37M | 1.06M |
| CurrentCapitalLeaseObligation | 1.85M | 3.38M | 3.37M | 1.06M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 9.97M | 10.01M | 8.40M | 6.65M |
| PayablesAndAccruedExpenses | 17.93M | 11.58M | 10.28M | 14.09M |
| CurrentAccruedExpenses | 14.62M | 11.25M | 3.14M | 12.45M |
| Payables | 3.31M | 337.00K | 7.15M | 1.64M |
| AccountsPayable | 3.31M | 337.00K | 7.15M | 1.64M |
| TotalAssets | 316.97M | 496.19M | 426.23M | 429.30M |
| TotalNonCurrentAssets | 2.92M | 17.92M | 38.28M | 13.69M |
| OtherNonCurrentAssets | 1.21M | 4.13M | 201.00K | |
| NonCurrentPrepaidAssets | 0.00 | 7.62M | ||
| NonCurrentDeferredAssets | 2.91M | 1.83M | ||
| InvestmentsAndAdvances | 0.00 | 9.85M | 23.51M | 0.00 |
| NetPPE | 2.92M | 6.86M | 10.64M | 4.04M |
| AccumulatedDepreciation | -2.05M | -1.44M | -1.06M | -598.00K |
| GrossPPE | 4.97M | 8.29M | 11.70M | 4.64M |
| Leases | 0.00 | 17.00K | 257.00K | |
| ConstructionInProgress | 0.00 | 41.00K | 514.00K | 215.00K |
| OtherProperties | 4.62M | 7.87M | 10.62M | 3.80M |
| MachineryFurnitureEquipment | 345.00K | 384.00K | 556.00K | 371.00K |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 314.06M | 478.28M | 387.95M | 415.60M |
| OtherCurrentAssets | 5.26M | 24.30M | ||
| RestrictedCash | 1.21M | 0.00 | 50.00K | 125.00K |
| PrepaidAssets | 23.36M | 15.10M | 6.03M | |
| Receivables | 939.00K | 919.00K | 200.00K | |
| OtherReceivables | 939.00K | 919.00K | 200.00K | |
| CashCashEquivalentsAndShortTermInvestments | 307.58M | 453.98M | 371.88M | 409.25M |
| OtherShortTermInvestments | 165.43M | 79.94M | 130.94M | 0.00 |
| CashAndCashEquivalents | 142.15M | 374.04M | 240.94M | 409.25M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -182.94M | -163.40M | -115.41M | -76.24M |
| RepurchaseOfCapitalStock | 0.00 | -491.00K | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 13.69M | 233.38M | 112.22M | 292.14M |
| CapitalExpenditure | -117.00K | -511.00K | -817.00K | |
| EndCashPosition | 143.36M | 375.25M | 242.21M | 409.37M |
| BeginningCashPosition | 375.25M | 242.21M | 409.37M | 192.10M |
| ChangesInCash | -231.89M | 133.04M | -167.17M | 217.27M |
| FinancingCashFlow | 21.60M | 231.94M | 115.74M | 293.51M |
| CashFlowFromContinuingFinancingActivities | 21.60M | 231.94M | 115.74M | 293.51M |
| NetOtherFinancingCharges | -3.80M | -744.00K | -1.14M | |
| ProceedsFromStockOptionExercised | 7.91M | 2.86M | 4.27M | 2.51M |
| NetPreferredStockIssuance | 0.00 | 0.00 | 112.22M | 291.18M |
| PreferredStockIssuance | 0.00 | 0.00 | 112.22M | 291.18M |
| NetCommonStockIssuance | 13.69M | 232.88M | 0.00 | 960.00K |
| CommonStockPayments | 0.00 | -491.00K | 0.00 | 0.00 |
| CommonStockIssuance | 13.69M | 233.38M | 0.00 | 960.00K |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -70.56M | 64.39M | -168.01M | -817.00K |
| CashFlowFromContinuingInvestingActivities | -70.56M | 64.39M | -168.01M | -817.00K |
| NetOtherInvestingChanges | -775.00K | -4.59M | -13.00M | |
| NetInvestmentPurchaseAndSale | -69.78M | 69.09M | -154.50M | 0.00 |
| SaleOfInvestment | 242.44M | 178.17M | 71.87M | 0.00 |
| PurchaseOfInvestment | -312.22M | -109.07M | -226.37M | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | -117.00K | -511.00K | -817.00K |
| PurchaseOfPPE | 0.00 | -117.00K | -511.00K | -817.00K |
| OperatingCashFlow | -182.94M | -163.28M | -114.90M | -75.42M |
| CashFlowFromContinuingOperatingActivities | -182.94M | -163.28M | -114.90M | -75.42M |
| ChangeInWorkingCapital | 22.64M | -8.90M | -6.95M | -961.00K |
| ChangeInOtherCurrentLiabilities | -3.38M | -3.40M | -1.83M | -841.00K |
| ChangeInOtherCurrentAssets | 0.00 | 0.00 | 1.37M | -3.66M |
| ChangeInPayablesAndAccruedExpense | 10.11M | 5.91M | -2.87M | 5.80M |
| ChangeInAccruedExpense | 7.24M | 6.49M | -1.62M | 6.56M |
| ChangeInPayable | 2.87M | -581.00K | -1.25M | -759.00K |
| ChangeInAccountPayable | 2.87M | -581.00K | -1.25M | -759.00K |
| ChangeInPrepaidAssets | 15.90M | -11.40M | -3.63M | -2.26M |
| OtherNonCashItems | 3.31M | 67.38M | 15.33M | 158.09M |
| StockBasedCompensation | 39.99M | 17.24M | 8.30M | 4.27M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | |||
| AssetImpairmentCharge | 0.00 | |||
| AmortizationOfSecurities | -5.72M | -3.74M | -708.00K | 0.00 |
| DepreciationAmortizationDepletion | 631.00K | 668.00K | 594.00K | 538.00K |
| DepreciationAndAmortization | 631.00K | 668.00K | 594.00K | 538.00K |
| OperatingGainsLosses | -559.00K | -53.00K | ||
| GainLossOnInvestmentSecurities | -559.00K | -53.00K | ||
| NetIncomeFromContinuingOperations | -243.79M | -235.93M | -130.90M | -237.31M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NMRA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|